Midatech Pharma : Description Report of Foreign Issuer

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF THE

SECURITIES EXCHANGE ACT OF 1934

For the month of, September 2019

Commission File Number 001-37652

Midatech Pharma PLC

(Translation of registrant's name into English)

Oddfellows House,

19 Newport Road,

Cardiff, CF24 0AA, United Kingdom

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-Fx Form 40-F¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

SUBMITTED HEREWITH

Attached to the Registrant's Form 6-K filing for the month of September 2019, and incorporated by reference herein, is:

Exhibit No. Description

99.1 Press release, dated September 9, 2019 entitled "Directorate Change."

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Midatech Pharma PLC

Date: September 9, 2019

By:

/s/ Stephen Stamp

Stephen Stamp

Chief Financial Officer

Exhibit Index

Exhibit No. Description

99.1 Press release, dated September 9, 2019 entitled "Directorate Change."

Exhibit 99.1

9 September 2019

Midatech Pharma PLC

("Midatech" or the "Company")

Directorate Change

Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), the R&D biotechnology company focused on delivering innovative oncology and rare disease products to patients, is pleased to announce the appointment of Stephen Stamp as a Director of the Company and as Chief Financial Officer with immediate effect.

Stephen Stamp is an experienced public company CFO and has held senior positions in a number of significant healthcare companies including as Group Finance Director of Shire plc, when the company was listed on the London Stock Exchange and NASDAQ, Chief Operating Officer of Xanodyne Pharmaceuticals Inc and most recently with AIM quoted Ergomed plc, where he served initially as CFO before becoming CEO. Mr Stamp qualified as a Chartered Accountant at KPMG and is a member of the Institute of Chartered Accountants.

Mr Stamp is taking over from Nick Robbins-Cherry, who has resigned as a Director of the Company with immediate effect to pursue other career opportunities. Mr Robbins-Cherry will remain employed by the Company until the end of October 2019 to facilitate an orderly handover to Mr Stamp.

Rolf Stahel, Midatech's Chairman commented: "The Directors are delighted to welcome Stephen Stamp to the Board of Midatech as CFO. He brings a wealth of relevant financial, commercial and industry experience gained in a wide range of senior roles at major healthcare companies, in the UK and internationally, which will enable him to make a significant contribution to Midatech's future success. This is an exciting time for the Company and having someone of Stephen's financial pedigree joining will be a real asset. I would also like to thank Nick Robbins-Cherry for his significant contribution and commitment to the Company over the past five years since our IPO and I wish him all the success in his next career move."

Craig Cook, Chief Executive of Midatech, commented: "I am excited that Stephen has agreed to join Midatech as CFO. He is a high calibre finance professional whose career to date makes him very well suited to support the execution of our strategy at this important and exciting time for the Company. Stephen's exceptional track record of both operational and financial leadership within the healthcare sector will deliver real benefit to Midatech. I very much look forward to working closely with him to drive forward the development of our business as we focus on getting our clinical research assets through clinical development, approval, and onto successful commercialisation. Whist I am sorry that Nick is leaving, I wish him well for the future and at the same time Stephen's appointment represents a very positive development for Midatech."

Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies

The following information is disclosed pursuant to Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies in relation to Mr Stephen Anthony Stamp, aged 57.

Current Directorships and Partnerships	Previous Directorships and Partnerships (past 5 years)
Berkeley Advisers Limited	Sound Opinion Limited
Storm Pharmaceuticals Inc	Harefield Pharmacovigilance Limited
Ergomed GmbH	Ergomed PLC
Ergomed Clinical Research FZ-LLC	Ergomed Clinical Research Limited
Ergomed Center for Data Management and Statistics GmbH	Primevigilance Limited
PrimeVigilance s.r.o.	Haemostatix Limited
Pharminvent regulatory s.r.o.	PSR Group BV
Ergomed Virtuoso sarl	Primevigilance Inc
	Ergomed Clinical Research Inc
	Ergomed Clinical Research Co Ltd